Who We Are
Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.
Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.
Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.
Key Issues
Causes We Care About, and So Should You!
HIV
Promote necessary funding, programs, and policies to end the HIV epidemic in the United States
HEPATITIS
Promote necessary funding, programs, and policies to end viral hepatitis in the United States
HEALTHCARE ACCESS
Promote necessary funding, programs, and policies to end viral hepatitis in the United States
Facebook posts by @HIV+Hep
Reduce prior authorization, don't just standardize it. That's our core message in our comments submitted to @CMSgov on its proposed #PriorAuth rule for drugs, including eliminating PAs for #HIV treatment & prevention & faster decision timeframes for #patients: bit.ly/4uBrzRq
Responding to Mississippi Insurance Department Commissioner Chaney’s refusal to enforce #ACA #PrEP no-copay rules, Carl Schmid said: “It is the insurance commissioner’s job to enforce the law, not to decide who deserves the protections to which they are entitled”: bit.ly/4vIYRiy
Mississippi Insurer Adds PrEP Coverage After Complaint, but Gaps Remain--Insurance Commissioner’s Remarks Raise Discrimination Concerns: bit.ly/4vIYRiy
New Medicaid Changes Under Trump Administration Raise Concerns for Seriously Ill Patients:
theheartysoul.com
New Medicaid work requirements force cancer patients to prove their illness prevents work or lose coverage.
Blue Cross Blue Shield Accused of Not Covering Certain HIV Meds:
Blue Cross Blue Shield Accused of Not Covering Certain HIV Meds
www.poz.com
Mississippi Commissioner asked to investigate insurer’s exclusion of HIV treatment and prevention meds despite federal requirements.